Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Trans-Atlantic VC Firm Invests in USA & Europe Startups Developing Early-Stage Technologies Across Biotech and Medtech

16 May

The firm is a trans-Atlantic venture investment firm focused on building innovative Life Sciences businesses in the UK, Europe and the USA. The firm has a highly experienced team that focuses on turning break-through science into approved medicines or medical products.

The firm starts and invests in early and mid-stage companies with a first-in-class or best-in-class approach. The investments are focused in new drug discovery – small molecules, biologics and new modalities – med tech, enabling technologies and vaccines.

The firm’s team are well connected team and experienced, and the team supports each investment. The firm works in close alignment with management teams, and partners with them to realize their vision and achieve financial returns by bringing innovation to patients.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Korea Investment Firm Seeks Novel Oncology, Immunology, Rare Disease Drugs & Platform Technologies in Pre-Clinical/Early Clinical Stage

9 May

An investment and management company headquartered in South Korea has ~$500M assets under management, and has a strong product/partnership portfolio in oncology, cardiovascular, CNS, anti-infection, among others. The firm has invested in an early-stage cell therapy company in South Korea, and is actively seeking early-stage (Seed to Series A) investment opportunities, and will also consider investments into VC funds that have aligned interest areas. The firm seeks to invest between $1-2M with capacity for up to $5M per company for initial investment, with potential for follow-on investments for promising companies that achieve milestones. The firm is actively seeking for global opportunities.

The firm is most interested in companies developing novel drugs in oncology, immunology, and rare disease indications and/or novel platform technologies for drug development. The firm will consider different types of modalities but is most interested in small molecules and biologics. In terms of stage of development, the firm is most interested in pre-clinical or early clinical stage companies.

The firm has a preference for working with experienced management teams – significant experience in drug development or senior management in global pharma or large biotech is considered a huge plus. The firm highly prefers companies that have a strong IP portfolio.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Family Office Firm Invests Up to $5M in Early-Stage, USA-Based Therapeutics Companies Across All Indications

9 May

A family office investment vehicle with offices in USA and Western Europe is looking to provide equity capital to USA-based therapeutic companies. The firm usually invests in Series A or B rounds, and will consider to participate in a seed round of financing. The firm’s typical deal size is variable, generally going as high as $5M for an initial investment.

The firm is currently looking for companies developing Therapeutics. The firm is opportunistic in terms of sub-sector and indication though they do have a preference for companies with platform technologies. The firm is willing to invest in companies with a lead asset in preclinical through Phase II of clinical trials. The firm’s portfolio includes oncology, the microbiome, pain, neurological and rare diseases biotech companies.

The firm looks to invest in companies with experienced management teams. The firm is capable to act as either a lead or a co-lead investor and generally seeks board or board observer rights. As a pro-active investor, The firm will assist in the growth of a company, recruit new talents, develop preclinical, clinical and IP strategies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: